Engineered immune cells take aim at stubborn blood cancers
NCT ID NCT02159495
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a new type of immunotherapy for patients with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has returned or not responded to treatment. Researchers take a patient's own (or a donor's) T-cells, modify them in the lab to recognize a protein called CD123 on cancer cells, and infuse them back after chemotherapy. The goal is to see if this approach is safe and what dose works best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T-cells (CD123-targeting CAR T-cells)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with hard-to-treat blood cancers like AML and BPDCN that have come back or not responded to standard therapy.
- What could go wrong
- This is an early phase 1 trial with only 31 participants, so it's primarily testing safety and dosing. The treatment may cause severe side effects, and it's too early to know if it will work broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE BIPHENOTYPIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?